Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Methode Electronics Inc. (NYSE: MEI) shares surged 43.07 percent to close at $35.28 a share Thursday. The stock traded between $30.30 and $35.58 on volume 4.50 million shares traded. The company reported net sales were $190.9 million for the second quarter of fiscal 2014, an increase of 47.1 percent when compared to a year ago. Shares of Methode Electronics have gained approximately 250.0 percent year-to-date.
Get more information on Methode Electronics and free access to the in-depth equity report at:
www.FiveStarEquities.com/MEI
Omnicare, Inc. (NYSE: OCR) shares gained 1.15 percent to close at $58.21 a share Thursday. The stock traded between $57.91 and $59.13 on volume 1.72 million shares traded. The company announced a quarterly dividend of $0.20 per share, an increase of 43.0 percent. Shares of Omnicare have gained approximately 60.0 percent year-to-date.
Get more information on Omnicare free access to the in-depth equity report at:
www.FiveStarEquities.com/OCR
Puma Biotechnology Inc. (NYSE: PBYI) shares soared 68.15 percent to close at $77.70 a share Thursday. The stock traded between $59.76 and $73.78 on volume 2.27 million shares traded. The company has reported positive top line data from its I-SPY 2 Trial. Shares of Puma Biotechnology have gained approximately 310.0 percent year-to-date.
Get more information on Puma Biotechnology and free access to the in-depth equity report at:
www.FiveStarEquities.com/PBYI
Synopsys, Inc. (NASDAQ: SNPS) shares increased 2.49 percent to close at $37.41 a share Thursday. The stock traded between $36.00 and $37.45 on volume of 1.96 million shares traded. The company reported revenues were $504.9 million for the fourth quarter of fiscal 2013, compared to $454.2 million a year ago. Shares of Synopsys have gained approximately 17.0 percent year-to-date.
Get more information on Synopsys and free access to the in-depth equity report at:
www.FiveStarEquities.com/SNPS
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]